Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Jing-Sheng CaiShuo LiShu-Mei YanJie YangMu-Zi YangChu-Long XieJi-Bin LiYan-Fen FengHao-Xian YangXue HouPublished in: Thoracic cancer (2021)
MPR combined with ND could improve the predictive value on survival in NSCLC patients receiving NAC.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- sentinel lymph node
- rectal cancer
- small cell lung cancer
- squamous cell carcinoma
- free survival
- radiation therapy
- transcription factor
- single cell
- cell therapy
- advanced non small cell lung cancer
- epidermal growth factor receptor
- stem cells
- liver metastases
- mesenchymal stem cells